Genomenon Logo 2020 - tag

About Us

Genomenon’s AI-driven genomic engine leverages billions of genetic associations between diseases, phenotypes and therapies found across the medical research. They deliver a comprehensive genomic landscape for every disease, including rare, neurodegenerative, and genetic diseases, as well as somatic and germline cancer.

Armed with a comprehensive base of molecular biomarkers and disease mechanisms, Genomenon’s customers expand their genetic knowledge of the disease drivers by a factor of 10-20X to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval.



Resource - Mastermind ALS

Team Members


Dr. Mark Kiel

Chief Science Officer & Co-Founder

Dave Anstey bio - circle-blank

Dave Anstey

Vice President, Sales and Business Development


Mike Klein

Chief Executive Officer


Erin MacCallum

Director of Sales